SG11201907848YA - Antibodies binding to vista at acidic ph - Google Patents
Antibodies binding to vista at acidic phInfo
- Publication number
- SG11201907848YA SG11201907848YA SG11201907848YA SG11201907848YA SG11201907848YA SG 11201907848Y A SG11201907848Y A SG 11201907848YA SG 11201907848Y A SG11201907848Y A SG 11201907848YA SG 11201907848Y A SG11201907848Y A SG 11201907848YA SG 11201907848Y A SG11201907848Y A SG 11201907848YA
- Authority
- SG
- Singapore
- Prior art keywords
- rte
- princeton
- box
- new jersey
- line road
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT omit VIII °nolo ominionni mom oimIE (10) International Publication Number WO 2018/169993 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/30 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/022230 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/471,196 14 March 2017 (14.03.2017) US 62/636,746 28 February 2018 (28.02.2018) US (71) Applicants: FIVE PRIME THERAPEUTICS, INC. [US/US]; 111 Oyster Point Blvd., South San Francisco, Cal- ifornia 94080 (US). BRISTOL-MYERS SQUIBB COM- PANY [US/US]; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). (72) Inventors: JOHNSTON, Robert J.; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). RAJPAL, Arvind; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). SHEP- PARD, Paul O.; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). BORGES, Luis; 111 Oyster Point Blvd., South San Francisco, California 94080 (US). RANKIN, Andrew; 111 Oyster Point Blvd., South San Francisco, California 94080 (US). BAHJAT, Keith; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). KORMAN, Alan; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). DENG, Andy X.; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). SU, Linhui Julie; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). RAKESTRAW, Ginger; Rte. 206 & Province Line Road, P.O. Box 4000, Princeton, New Jersey 08543 (US). (74) Agent: DOHERTY, Elizabeth et al.; McNeill Baur PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massa- chusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: ANTIBODIES BINDING TO VISTA AT ACIDIC PH v7 TA .9.00 Etpleigth 01 01 01 FIG. 1A (57) : The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppres- sor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically © to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. C [Continued on next page] WO 2018/169993 Al MIDEDIMOMOIDEIREEMOMOHIMEHOHMOIMEN CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762471196P | 2017-03-14 | 2017-03-14 | |
US201862636746P | 2018-02-28 | 2018-02-28 | |
PCT/US2018/022230 WO2018169993A1 (en) | 2017-03-14 | 2018-03-13 | Antibodies binding to vista at acidic ph |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907848YA true SG11201907848YA (en) | 2019-09-27 |
Family
ID=63522565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907848YA SG11201907848YA (en) | 2017-03-14 | 2018-03-13 | Antibodies binding to vista at acidic ph |
Country Status (16)
Country | Link |
---|---|
US (2) | US11603406B2 (en) |
EP (1) | EP3595720A4 (en) |
JP (2) | JP7211961B2 (en) |
KR (1) | KR20190128198A (en) |
CN (1) | CN110740749A (en) |
AU (1) | AU2018236218A1 (en) |
BR (1) | BR112019019108A2 (en) |
CA (1) | CA3054067A1 (en) |
CL (2) | CL2019002610A1 (en) |
CO (1) | CO2019010943A2 (en) |
IL (1) | IL269240A (en) |
MY (1) | MY200609A (en) |
PE (1) | PE20191708A1 (en) |
SG (1) | SG11201907848YA (en) |
TW (1) | TWI825010B (en) |
WO (1) | WO2018169993A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
CA2857159C (en) | 2011-11-30 | 2024-05-07 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
KR20230110836A (en) | 2012-08-24 | 2023-07-25 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb-specific Fc region variant |
ES2644022T3 (en) * | 2013-03-14 | 2017-11-27 | Bristol-Myers Squibb Company | Combination of a DR5 agonist and an anti-PD-1 antagonist and methods of use |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
ES2899894T3 (en) | 2014-12-19 | 2022-03-15 | Chugai Pharmaceutical Co Ltd | Anti-C5 antibodies and methods of use |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
EA201791754A1 (en) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | ANTIBODIES CONTAINING ANTIGEN-BINDING DOMAIN DEPENDING ON THE CONCENTRATION OF IONS, Fc-AREA OPTIONS, IL-8-CONNECTING ANTIBODIES AND THEIR APPLICATIONS |
JP7141336B2 (en) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | Anti-myostatin antibodies and methods of use |
CN109689099B (en) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | Composition for preventing or treating IL-8-related diseases |
EP3568159A4 (en) | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | Psgl-1 antagonists and uses thereof |
JP7191833B2 (en) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | Anti-sclerostin antibodies and uses thereof |
MY200609A (en) | 2017-03-14 | 2024-01-05 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
CN110621697B (en) | 2017-05-25 | 2023-06-27 | 百时美施贵宝公司 | Antagonistic CD40 monoclonal antibodies and uses thereof |
JP2021518133A (en) * | 2018-03-21 | 2021-08-02 | ファイブ プライム セラピューティクス, インコーポレイテッド | Antibodies that bind to VISTA at acidic pH |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
US20220073617A1 (en) * | 2018-07-11 | 2022-03-10 | Five Prime Therapeutics, Inc. | Antibodies Binding to Vista at Acidic pH |
CN112740043A (en) * | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | VISTA receptor |
AR117091A1 (en) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES |
JP2022548292A (en) * | 2019-09-19 | 2022-11-17 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies that bind VISTA at acidic pH |
IL310292A (en) | 2021-07-22 | 2024-03-01 | Univ Dundee | Therapeutic muteins |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997913A (en) | 1986-06-30 | 1991-03-05 | Oncogen | pH-sensitive immunoconjugates and methods for their use in tumor therapy |
US5605821A (en) | 1989-03-08 | 1997-02-25 | Board Of Regents Of The University Of Oklahoma | Expression control sequences of the P-selectin gene |
CA2086323C (en) | 1990-07-17 | 2002-05-14 | Rodger P. Mcever | Functionally active selectin-derived peptides and ligand for gmp-140 |
US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
ATE501254T1 (en) | 1992-10-23 | 2011-03-15 | Genetics Inst Llc | P-SELECTIN LIGAND PROTEIN |
WO1994011498A1 (en) | 1992-11-16 | 1994-05-26 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for p-selectin and methods of use thereof |
WO1995030001A2 (en) | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
AU723262B2 (en) | 1995-08-03 | 2000-08-24 | Board Of Regents Of The University Of Oklahoma, The | Peptide and O-glycan inhibitors of selectin mediated inflammation |
WO1997009068A2 (en) | 1995-09-01 | 1997-03-13 | University Of Washington | Interactive molecular conjugates |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2002508167A (en) | 1997-12-18 | 2002-03-19 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 110 human secreted proteins |
EP1090118A2 (en) | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
WO2001004297A2 (en) | 1999-07-08 | 2001-01-18 | Sagami Chemical Research Center | Human proteins having hydrophobic domains and dnas encoding these proteins |
CA2404310A1 (en) | 2000-03-24 | 2001-10-04 | Meike Lorenz | A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor |
US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
EP1511861A4 (en) | 2002-06-12 | 2007-12-05 | Genencor Int | Methods and compositions for milieu-dependent binding of a targeted agent to a target |
WO2004022594A2 (en) | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US20050260711A1 (en) * | 2004-03-30 | 2005-11-24 | Deepshikha Datta | Modulating pH-sensitive binding using non-natural amino acids |
MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
EP1751300B1 (en) | 2004-05-11 | 2017-11-08 | AbGenomics Coöperatief U.A. | T-cell death-inducing epitopes |
ES2405273T3 (en) | 2004-06-24 | 2013-05-30 | Mayo Foundation For Medical Education And Research | Costimulatory polypeptide B7-H5 |
WO2006116181A2 (en) | 2005-04-25 | 2006-11-02 | Trustees Of Dartmouth College | Regulatory t cell mediator proteins and uses thereof |
WO2007033959A2 (en) | 2005-09-19 | 2007-03-29 | Vib Vzw | Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas |
WO2007067984A2 (en) | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
JP2010505435A (en) * | 2006-10-11 | 2010-02-25 | アブリンクス エン.ヴェー. | Amino acid sequences that bind to serum proteins essentially independently of pH, compounds containing them, and uses thereof |
EP2291536A4 (en) | 2008-05-15 | 2013-02-27 | Selexys Pharmaceuticals Corp | Anti-psgl-1 antibodies and methods of identification and use |
MX2011007833A (en) * | 2009-01-23 | 2011-10-06 | Biogen Idec Inc | Stabilized fc polypeptides with reduced effector function and methods of use. |
NO2406399T3 (en) * | 2009-03-09 | 2018-07-14 | ||
CA2794483C (en) * | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
KR20130096731A (en) | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | Methods for assessing and identifying or evolving conditionally active therapeutic proteins |
BR112013031892A2 (en) | 2011-06-13 | 2016-11-22 | Abgenomics Cooperatief Ua | anti-psgl-1 antibodies and their use |
CN104159918B (en) * | 2011-10-28 | 2019-09-13 | 生物国际神经系统科学公司 | TDP-43 specific binding molecules |
WO2013082200A1 (en) | 2011-11-28 | 2013-06-06 | Shaw Gray D | Novel enhanced selectin antagonists |
US20140170159A9 (en) * | 2012-03-08 | 2014-06-19 | Ge Wei | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
WO2015109340A2 (en) | 2014-01-14 | 2015-07-23 | Noelle Randolph J | Vista antagonist and methods of use |
WO2014039983A1 (en) * | 2012-09-07 | 2014-03-13 | The Trustees Of Dartmouth College | Vista modulators for diagnosis and treatment of cancer |
FI3421486T3 (en) | 2012-06-22 | 2023-12-15 | Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
AU2014268298B2 (en) | 2013-05-24 | 2019-01-17 | Medlmmune, Llc | Anti-B7-H5 antibodies and their uses |
SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
AU2014346852A1 (en) | 2013-11-05 | 2016-06-16 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
JP6590810B2 (en) * | 2013-12-24 | 2019-10-16 | ヤンセン ファーマシューティカ エヌブイ | Anti-VISTA antibodies and fragments |
WO2015187359A1 (en) | 2014-06-04 | 2015-12-10 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for targeting a pathway |
WO2015191881A2 (en) | 2014-06-11 | 2015-12-17 | Green Kathy A | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
CA2953706A1 (en) | 2014-07-08 | 2016-01-14 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
JOP20150008B1 (en) * | 2014-11-26 | 2021-08-17 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
CA2969730A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
PL3333191T3 (en) | 2014-12-11 | 2021-05-04 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
WO2016196228A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
BR112017027870A2 (en) | 2015-06-24 | 2018-08-28 | Janssen Pharmaceutica Nv | antibodies and anti-sight fragments |
CN115521374A (en) | 2015-11-02 | 2022-12-27 | 生物蛋白有限公司 | Conditionally active polypeptides |
CN108713026B (en) | 2016-01-08 | 2023-01-06 | 美国全心医药生技股份有限公司 | Tetravalent anti-PSGL-1 antibodies and uses thereof |
WO2017137830A1 (en) * | 2016-02-12 | 2017-08-17 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
UA125382C2 (en) | 2016-04-15 | 2022-03-02 | Імьюнекст Інк. | Anti-human vista antibodies and use thereof |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
WO2018047143A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Vista signaling pathway inhibitory compounds useful as immunomodulators |
EP3568159A4 (en) | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | Psgl-1 antagonists and uses thereof |
MY200609A (en) | 2017-03-14 | 2024-01-05 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
CA3067835A1 (en) | 2017-06-22 | 2018-12-27 | Apexigen, Inc. | Anti-vista antibodies and methods of use |
BR112020007755A2 (en) | 2017-10-20 | 2020-10-20 | Pharmabcine Inc. | anti-sight antibody and use of it |
EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
JP7084569B2 (en) | 2018-02-23 | 2022-06-15 | トゥルーバインディング,インコーポレイテッド | Cancer treatment by blocking the interaction of VISTA and its binding partners |
JP2021518133A (en) | 2018-03-21 | 2021-08-02 | ファイブ プライム セラピューティクス, インコーポレイテッド | Antibodies that bind to VISTA at acidic pH |
US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
WO2019185163A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Vista antigen-binding molecules |
US20220073617A1 (en) | 2018-07-11 | 2022-03-10 | Five Prime Therapeutics, Inc. | Antibodies Binding to Vista at Acidic pH |
CN109878421B (en) | 2019-03-13 | 2020-11-03 | 浙江吉利控股集团有限公司 | Vehicle ramp device and automobile |
CN110563843A (en) | 2019-07-25 | 2019-12-13 | 钟小泉 | Monoclonal antibody targeting human VISTA protein |
-
2018
- 2018-03-13 MY MYPI2019004903A patent/MY200609A/en unknown
- 2018-03-13 KR KR1020197029923A patent/KR20190128198A/en not_active Application Discontinuation
- 2018-03-13 PE PE2019001859A patent/PE20191708A1/en unknown
- 2018-03-13 AU AU2018236218A patent/AU2018236218A1/en active Pending
- 2018-03-13 EP EP18767615.0A patent/EP3595720A4/en active Pending
- 2018-03-13 WO PCT/US2018/022230 patent/WO2018169993A1/en unknown
- 2018-03-13 US US16/493,712 patent/US11603406B2/en active Active
- 2018-03-13 BR BR112019019108A patent/BR112019019108A2/en unknown
- 2018-03-13 SG SG11201907848YA patent/SG11201907848YA/en unknown
- 2018-03-13 CA CA3054067A patent/CA3054067A1/en active Pending
- 2018-03-13 JP JP2019549389A patent/JP7211961B2/en active Active
- 2018-03-13 CN CN201880031212.2A patent/CN110740749A/en active Pending
- 2018-03-14 TW TW107108715A patent/TWI825010B/en active
-
2019
- 2019-09-10 IL IL26924019A patent/IL269240A/en unknown
- 2019-09-12 CL CL2019002610A patent/CL2019002610A1/en unknown
- 2019-10-02 CO CONC2019/0010943A patent/CO2019010943A2/en unknown
-
2021
- 2021-10-21 CL CL2021002769A patent/CL2021002769A1/en unknown
-
2023
- 2023-01-12 JP JP2023002879A patent/JP2023061927A/en active Pending
- 2023-02-01 US US18/162,991 patent/US20240092907A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240092907A1 (en) | 2024-03-21 |
WO2018169993A1 (en) | 2018-09-20 |
PE20191708A1 (en) | 2019-11-28 |
US20200055936A1 (en) | 2020-02-20 |
TW201843171A (en) | 2018-12-16 |
US11603406B2 (en) | 2023-03-14 |
CO2019010943A2 (en) | 2020-01-17 |
MY200609A (en) | 2024-01-05 |
JP2023061927A (en) | 2023-05-02 |
AU2018236218A1 (en) | 2019-09-12 |
CL2019002610A1 (en) | 2019-11-29 |
KR20190128198A (en) | 2019-11-15 |
EP3595720A4 (en) | 2021-05-26 |
JP2020509756A (en) | 2020-04-02 |
IL269240A (en) | 2019-11-28 |
TWI825010B (en) | 2023-12-11 |
CL2021002769A1 (en) | 2022-08-12 |
BR112019019108A2 (en) | 2020-04-22 |
CN110740749A (en) | 2020-01-31 |
CA3054067A1 (en) | 2018-09-20 |
JP7211961B2 (en) | 2023-01-24 |
EP3595720A1 (en) | 2020-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201810883TA (en) | Combination therapy | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201804127SA (en) | Ctla4 binders | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201900501RA (en) | Cannabis composition | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201908678XA (en) | Methods and compositions for reduction of immunogenicity |